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Measuring the health of nations: analysis of mortality
amenable to health care
Ellen Nolte, Martin McKee
Abstract
Objective To assess whether and how the rankings of
the world’s health systems based on disability adjusted
life expectancy as done in the 2000 World Health
Report change when using the narrower concept of
mortality amenable to health care, an outcome more
closely linked to health system performance.
Design Analysis of mortality amenable to health care
(including and excluding ischaemic heart disease).
Main outcome measure Age standardised mortality
from causes amenable to health care
Setting 19 countries belonging to the Organisation
for Economic Cooperation and Development.
Results Rankings based on mortality amenable to
health care (excluding ischaemic heart disease)
differed substantially from rankings of health
attainment given in the 2000 World Health Report. No
country retained the same position. Rankings for
southern European countries and Japan, which had
performed well in the report, fell sharply, whereas
those of the Nordic countries improved. Some middle
ranking countries (United Kingdom, Netherlands)
also fell considerably; New Zealand improved its
position. Rankings changed when ischaemic heart
disease was included as amenable to health care.
Conclusion The 2000 World Health Report has been
cited widely to support claims for the merits of
otherwise different health systems. High levels of
health attainment in well performing countries may
be a consequence of good fortune in geography, and
thus dietary habits, and success in the health effects of
policies in other sectors. When assessed in terms of
achievements that are more explicitly linked to health
care, their performance may not be as good.
Introduction
In its 2000 World Health Report, the World Health
Organization published a set of rankings of the world’s
health systems.1 In brief, the overall performance of the
health systems was assessed as a composite measure
including level and distribution of health attainment,
responsiveness of the health system, and degree of fair-
ness of financing. Aggregate performance was com-
pared with what might be expected given the country’s
level of economic and educational development.
This approach has attracted intensive debate, rang-
ing from the implied values underlying the approach
to technical considerations.2 3 Despite the volume of
debate, a recent review characterised this process as a
dialogue of the deaf.4
One issue still unresolved is the attribution of
health attainment to health systems.5 The World Health
Report refers to growing evidence of health gains to be
achieved from health care and from health related
policies in other sectors, such as vehicle safety.
However, many determinants of health still lie outside
health care. One possible solution uses mortality data
at a population level that are available in many
countries and is based on the concept that deaths from
certain causes should not occur in the presence of
timely and effective health care. This has given rise to
the development of a variety of terms including
“avoidable mortality” and “mortality amenable to
medical/health care.”6 Originally developed in the
mid-1970s to measure the quality of health care, the
concept was subsequently adopted widely, especially in
Europe.7–10
The 2000 World Health Report approvingly cited
research on amenable mortality but then used a much
broader measure of health, disability adjusted expect-
ancy, without attempting to disaggregate mortality that
is and is not amenable to health care. The broad defi-
nition of a health system that this implies is, however,
inconsistent with the scope of the other two measures
used in the report, responsiveness and fairness of
financing, which relate directly to the healthcare
system. An important question emerging from this
debate is whether and how rankings of health systems
change when using a more clearly defined measure of
health system outcome, mortality amenable to health
care. We compared the results achieved by the two
approaches in industrialised countries.
Methods
Mortality and population data were extracted from
WHO mortality files for 1998 (1997 for Canada).11
Data include deaths, coded according to the ninth and
10th revisions of the international classification of dis-
eases, by sex and five year age bands (with infant deaths
listed separately).
Data were examined for the countries of western
Europe, the United States, Canada, Australia, New Zea-
land, and Japan, countries with high quality mortality
data by cause of death. We excluded countries if data
were unavailable for years more recent than 1996 (Bel-
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gium, Switzerland) and those with small populations
(Luxemburg, Iceland).
The selection of causes of death considered
amenable to health care was derived from a recent
review of “avoidable” mortality.6 The detailed justifica-
tion for selection of conditions is set out in that review
but, in brief, the final list was a modification of work by
Tobias and Jackson, who updated earlier work by
Mackenbach and Charlton and coworkers (table).8 12 13
As in our earlier work, an age limit was set at 75
years, as avoidability of death and reliability of death
certification become increasingly questionable at older
ages. We recognise that any upper age limit is
essentially arbitrary, but this value is consistent with life
expectancy at birth in many industrialised countries.
However the logic of this would suggest setting differ-
ent limits for men and women because of the sex gap
in life expectancy. We recognise this as an important
issue for debate, but we do not believe that it has yet
been resolved.
Different age limits were set for diabetes mellitus
(under 50) because the preventability of deaths at older
ages from diabetes remains controversial. For some
other causes, a limit of 15 years was set (see table) as
related deaths other than in childhood are likely to
reflect some other disease process. The age limit for
leukaemia was extended to 44 years because of recent
evidence showing substantial improvements in mor-
tality from leukaemia in the European Union up to age
44 since 1960.14
To calculate mortality from conditions amenable to
health care, we combined single causes and groups of
causes. We computed age standardised death rates per
100 000 population, for both sexes combined, by direct
standardisation to the European standard popula-
tion.15 Ischaemic heart disease was treated separately,
as the precise contribution of health care to reductions
in deaths from this condition remains unresolved.16
However, accumulating evidence suggests its impact to
be considerable, indicating that up to 50% of
premature mortality from ischaemic heart disease may
be amenable to health care.12 To account for this we ran
two sets of analyses, with and without ischaemic heart
disease. Where we included ischaemic heart disease we
assumed 50% of deaths under the age of 75 to be ame-
nable to health care.
Based on age standardised death rates derived in
this way we constructed rankings for the countries
included in this analysis, supplemented with similar
rankings for data on disability adjusted life expectancy
for 1999, which were taken from the 2000 World Health
Report.1 Rankings were then compared for perform-
ance in terms of both disability adjusted life expectancy
and amenable mortality.
Causes of death considered amenable to health care
Cause of death Age
International classification of diseases
9th revision 10th revision
Intestinal infections 0-14 001-9 A00-9
Tuberculosis 0-74 010-8, 137 A15-9, B90
Other infections (diphtheria, tetanus, poliomyelitis) 0-74 032, 037, 045 A36, A35, A80
Whooping cough 0-14 033 A37
Septicaemia 0-74 038 A40-1
Measles 1-14 055 B05
Malignant neoplasm of colon and rectum 0-74 153-4 C18-21
Malignant neoplasm of skin 0-74 173 C44
Malignant neoplasm of breast 0-74 174 C50
Malignant neoplasm of cervix uteri 0-74 180 C53
Malignant neoplasm of cervix uteri and body of uterus 0-44 179, 182 C54, C55
Malignant neoplasm of testis 0-74 186 C62
Hodgkin’s disease 0-74 201 C81
Leukaemia 0-44 204-8 C91-5
Diseases of the thyroid 0-74 240-6 E00-7
Diabetes mellitus 0-49 250 E10-4
Epilepsy 0-74 345 G40-1
Chronic rheumatic heart disease 0-74 393-8 I05-9
Hypertensive disease 0-74 401-5 I10-3, I15
Cerebrovascular disease 0-74 430-8 I60-9
All respiratory diseases (excluding pneumonia and influenza) 1-14 460-79, 488-519 J00-9, J20-99
Influenza 0-74 487 J10-1
Pneumonia 0-74 480-6 J12-8
Peptic ulcer 0-74 531-3 K25-7
Appendicitis 0-74 540-3 K35-8
Abdominal hernia 0-74 550-3 K40-6
Cholelithiasis and cholecystitis 0-74 574-5.1 K80-1
Nephritis and nephrosis 0-74 580-9 N00-7, N17-9, N25-7
Benign prostatic hyperplasia 0-74 600 N40
Maternal death All 630-76 O00-99
Congenital cardiovascular anomalies 0-74 745-7 Q20-8
Perinatal deaths, all causes, excluding stillbirths All 760-79 P00-96, A33
Misadventures to patients during surgical and medical care All E870-6, E878-9 Y60-9, Y83-4
Ischaemic heart disease* 0-74 410-4 I20-5
*See text.
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Results
Figure 1 shows the rankings for the 19 countries
included in our analysis based on disability adjusted
life expectancy and on amenable mortality without
ischaemic heart disease, showing that no country
retained the same rank with both methods. Twelve of
the countries moved more than two ranks.Major losses
using amenable mortality were seen for Japan (from 1
to 13), Greece (7 to 12), and the United Kingdom (10
to 18). Large gains were seen for Canada (9 to 4), Nor-
way (11 to 2), Finland (13 to 8), Germany (14 to 6),
Denmark (17 to 10), and New Zealand (19 to 15). A few
broad trends were observed in groups of countries
that, at least in other respects, share particular charac-
teristics. The Nordic countries ranked higher using
amenable mortality, in several cases noticeably so.
Southern European countries, whose high rankings
have often been attributed to the known effects of a
Mediterranean diet, had all fallen. The situation with
the non-European countries is more mixed. Australia
remained among the top five ranking countries with
both measures whereas New Zealand, despite being
placed four ranks higher with amenable mortality,
remained in the bottom half of the ranking.
Figure 2 shows the rankings of the 19 countries for
disability adjusted life expectancy compared with mor-
tality amenable to health care with ischaemic heart dis-
ease. Rankings changed for all but two (Mediterranean)
countries. Major losses were again seen for Greece
(from 7 to 12) and particularly for the United Kingdom
(10 to 19) but also for the Netherlands (8 to 11) and
Australia (2 to 7). The Nordic countries generally
showed substantial improvements in their rankings,
especially Denmark (17 to 10) and Norway (11 to 5),
but not Finland (13 to 15). With the exception of
Greece, southern European countries retained either
similar ranks to the report (Italy, Portugal) or improved
(Spain, France). For the other countries the rankings
based on amenable mortality with ischaemic heart
disease were essentially similar to those based on
amenable mortality without ischaemic heart disease.
The only other exception was Japan, which, with the
inclusion of ischaemic heart disease, remained among
the top five ranking countries.
Discussion
Rankings based on mortality amenable to health care
produce results different from those based on disability
adjusted life expectancy, as used in the 2000 World
Health Report. This highlights the problems involved in
international comparisons.
The quest for accountability has generated an
industry engaged in ranking performance in many dif-
ferent sectors. This approach developed from control
systems in industrial management, where it has long
been used with processes where the inputs and
products are simple and unambiguous, and there are
few if any extraneous factors. It is intuitively appealing,
especially to politicians who are anxious to know how
public funds are being spent. It is seen as a means to
reduce a mass of complex information into a format
that almost anyone can understand. Yet its apparent
simplicity can be misleading, and many commentators
have noted numerous technical problems, ranging
from lack of validity to creation of perverse incentives
as those involved change their practice or recording
methods to achieve higher rankings, despite leading to
worse performance.
We have looked at one of many possible issues
related to health system rankings that has so far been
unexplored. The hypothesis was that a measure of
health attainment more closely linked to the health-
care system would produce a systematically different
ranking. This hypothesis was confirmed, with the
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Nordic countries doing better than in the WHO model
of the 2000 report.
However we do not argue that amenable mortality
should substitute disability adjusted life expectancy
even if performance was to be ranked. Firstly, it is
impossible to rank all countries by amenable mortality
given the widespread absence of data by diagnosis. It
should be noted, though, that lack of even total
mortality for many countries was not seen as an obsta-
cle by the authors of the 2000 World Health Report, who
used regression modelling to impute figures for
disability adjusted life expectancy. A recent study that
looked at the method used in the report to generate
data on disability adjusted life expectancy showed that,
where actual data became available, the regression
result produced a quite different value.17
Secondly, amenable mortality has itself some
limitations. The diagnostic categories and the age
range used involve some choices that are inevitably
arbitrary. A major limitation is that, for many
conditions, death is the final event in a complex chain
of processes that involve issues related to underlying
social and economic factors, lifestyles, and preventive
and curative health care. Partitioning deaths among
the categories is an inexact science. The example of
ischaemic heart disease is instructive. Accumulating
evidence suggests that advances in health care have
contributed to the fall in mortality from ischaemic
heart disease in many countries, yet it is equally clear
that large international differences in mortality are
caused primarily by factors outside the healthcare
sector.16 18–21 Thus our second analysis included only
50% of mortality from ischaemic heart disease.
Obviously many different proportions could be used,
from 40% up to 70%, and the choice may vary by
country.16 22 However, it is important to note that the
inclusion of ischaemic heart disease in our measure of
healthcare outcomes again changes the rankings of
countries compared with those of the 2000 World
Health Report. This highlights the problems associated
with rankings that are based on summary measures, as
they can be sensitive to underlying definitions and
concepts.
Furthermore, what is considered amenable to
health care will change over time as new pharmaceuti-
cals and management strategies are developed. Thus
testicular cancer has now become potentially a largely
curable disease, although the extent to which this is
achieved by different healthcare systems varies.23 In the
future it is plausible that diseases such as prostatic can-
cer and AIDS could become amenable, with potentially
important consequences for such rankings.
The upper age limit is also problematic. We
included deaths only up to age 75, although it is also
clear that advances in medical care are making an
increasingly large contribution to survival of people at
older ages. Conversely, there remains uncertainty
about the validity of death certification at these ages in
many countries, not least because of the problems cre-
ated by comorbidity. We also only looked at rankings
for both sexes combined, although a subsequent analy-
sis showed that in some cases rankings differed by sex
(data not shown), largely reflecting the relative import-
ance of breast cancer as a cause of premature death in
women in the country in question.
So how can amenable mortality be used to under-
stand the performance of a health system? We argue
that it does have some value, but not in terms of the
aggregate values (although arguably the rankings pro-
duced by amenable mortality have greater face validity
than those using disability adjusted life expectancy).
Instead, it enables comparison of the elements that
make up the overall figure, permitting investigators to
dig down to look at specific policies and learn from dif-
ferent experiences. In some cases these differences are
already recognised, examples including advances in
early detection and treatment of stomach cancer in
Japan and of melanoma in Australia.24 25 Of course,
whether these policies can or should be transferred
between countries depends on the burden of disease
involved and other contextual factors.
It now seems unlikely that the exercise to rank per-
formance of health systems will be repeated, but this
does not mean that the quest to identify improved
measures of performance will be abandoned.What our
study shows is that rankings based on overall health
attainment and health attainment that can, however
imperfectly, be more closely linked to health care, pro-
duce different results.
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